The AHA and American Society of Health-System Pharmacists today urged the Food and Drug Administration to take appropriate enforcement action to protect patients from a payer-mandated drug distribution model known as “white bagging.” 

Under the white bagging model, commercial health insurers require that patient medications be distributed through a narrow network of specialty pharmacies, often affiliated with the payer. Providers are then required to receive, store and administer the medications without ever taking ownership of the product or having adequate line of sight into the origin or chain of custody of each specific medication it receives, potentially jeopardizing patient safety and limiting the ability of providers to make critical care decisions for their patients. 

“White bagging has surged in frequency over the past decade, creating what amounts to a shadow inventory that hospitals and health systems do not legally own and which exists largely outside of the [Drug Supply Chain Security Act’s] track and trace requirements,” jeopardizing patient safety and exacerbating supply chain security challenges, the organizations said.
 

Related News Articles

Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed…
Headline
The AHA Jan. 28 voiced support for bipartisan legislation to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act, which provides…
Chairperson's File
There is so much for health care leaders to navigate when it comes to public policy and government relations. Thankfully, the AHA has an expert team with…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Perspective
All eyes this week have been on Washington, D.C., as President Trump was inaugurated and the 119th Congress — with Republicans holding majorities in the House…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…